LUCID DIAGNOSTICS INC (LUCD) Stock Price & Overview
NASDAQ:LUCD • US54948X1090
Current stock price
The current stock price of LUCD is 1.305 USD. Today LUCD is up by 1.95%. In the past month the price increased by 2.4%. In the past year, price decreased by -3.76%.
LUCD Key Statistics
- Market Cap
- 230.92M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.80
- Dividend Yield
- N/A
LUCD Stock Performance
LUCD Stock Chart
LUCD Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to LUCD. When comparing the yearly performance of all stocks, LUCD is a bad performer in the overall market: 60.45% of all stocks are doing better.
LUCD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LUCD. Both the profitability and financial health of LUCD have multiple concerns.
LUCD Earnings
On March 25, 2026 LUCD reported an EPS of -0.1 and a revenue of 1.50M. The company beat EPS expectations (1.96% surprise) and beat revenue expectations (8.44% surprise).
LUCD Forecast & Estimates
11 analysts have analysed LUCD and the average price target is 4.03 USD. This implies a price increase of 208.74% is expected in the next year compared to the current price of 1.305.
For the next year, analysts expect an EPS growth of 65.49% and a revenue growth 118.08% for LUCD
LUCD Groups
Sector & Classification
LUCD Financial Highlights
Over the last trailing twelve months LUCD reported a non-GAAP Earnings per Share(EPS) of -0.8. The EPS increased by 24.53% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -174.48% | ||
| ROE | -645.29% | ||
| Debt/Equity | 2.19 |
LUCD Ownership
LUCD Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 14.62 | 161.117B | ||
| ISRG | INTUITIVE SURGICAL INC | 41.42 | 160.285B | ||
| SYK | STRYKER CORP | 21.79 | 125.349B | ||
| BSX | BOSTON SCIENTIFIC CORP | 18.52 | 88.457B | ||
| EW | EDWARDS LIFESCIENCES CORP | 27 | 45.956B | ||
| IDXX | IDEXX LABORATORIES INC | 38.96 | 45.191B | ||
| BDX | BECTON DICKINSON AND CO | 11.39 | 44.616B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 13.78 | 32.972B | ||
| RMD | RESMED INC | 18.07 | 32.227B | ||
| DXCM | DEXCOM INC | 24.84 | 24.092B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.94 | 17.942B | ||
| PODD | INSULET CORP | 29.76 | 13.321B | ||
| PEN | PENUMBRA INC | 65.12 | 12.858B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LUCD
Company Profile
Lucid Diagnostics, Inc. is a commercial-stage medical diagnostics technology company. The company is headquartered in New York City, New York and currently employs 72 full-time employees. The company went IPO on 2021-10-14. The firm is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard and EsoCheck. EsoGuard is a bisulfite-converted next generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. The company consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. The company is also developing EsoCure, is an Esophageal Ablation Device, which is a technology that allows a clinician to treat dysplastic BE.
Company Info
IPO: 2021-10-14
LUCID DIAGNOSTICS INC
360 Madison Avenue, 25th Floor
New York City NEW YORK US
Employees: 82
Phone: 12129494319
LUCID DIAGNOSTICS INC / LUCD FAQ
What does LUCD do?
Lucid Diagnostics, Inc. is a commercial-stage medical diagnostics technology company. The company is headquartered in New York City, New York and currently employs 72 full-time employees. The company went IPO on 2021-10-14. The firm is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard and EsoCheck. EsoGuard is a bisulfite-converted next generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. The company consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. The company is also developing EsoCure, is an Esophageal Ablation Device, which is a technology that allows a clinician to treat dysplastic BE.
Can you provide the latest stock price for LUCID DIAGNOSTICS INC?
The current stock price of LUCD is 1.305 USD. The price increased by 1.95% in the last trading session.
Does LUCID DIAGNOSTICS INC pay dividends?
LUCD does not pay a dividend.
What is the ChartMill technical and fundamental rating of LUCD stock?
LUCD has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the growth outlook for LUCID DIAGNOSTICS INC?
The Revenue of LUCID DIAGNOSTICS INC (LUCD) is expected to grow by 118.08% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is LUCID DIAGNOSTICS INC worth?
LUCID DIAGNOSTICS INC (LUCD) has a market capitalization of 230.92M USD. This makes LUCD a Micro Cap stock.
What is the ownership structure of LUCID DIAGNOSTICS INC (LUCD)?
You can find the ownership structure of LUCID DIAGNOSTICS INC (LUCD) on the Ownership tab.